Active	Status	Sponsor type	Region	Phase	Filter
1 Active 1 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
alpibectir (BVL-GSK098) / BioVersys, GSK
BETO, NCT05473195: A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098	Recruiting	2	105	RoW	BVL-GSK098 9mg, Ethionamide 125 and 250mg, Ethionamide 250mg, Ethionamide 250 mg, Isoniazid 300 MG	TASK Applied Science	Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB)	10/23	10/23